ClinicalTrials.gg
CompletedNCT05703373Updated Aug 20, 2026

Increasing Access to Multiple Micronutrient Supplementation - A Pilot Intervention at up to 15 Clinics in Botswana

An interventional study of Multiple Micronutrient Supplement in Pregnancy Related, sponsored by University of Pennsylvania. Completed at 13 sites in Botswana. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
1,210
Allocation
Not applicable
Sex
Female
01

Study summary

The purpose of this study is to pilot a clinic-level supplementation intervention at up to 15 antenatal clinics throughout Botswana. The overall objective of this study is to improve access to and uptake of MMS among pregnant women in Botswana. The investigators will evaluate both implementation outcomes (adoption, penetration, fidelity, and feasibility) and clinical outcomes (adverse birth outcomes, weight gain in pregnancy, and anemia) through linkage with the Tsepamo birth outcomes surveillance study.

02

Conditions studied

  • Pregnancy Related
03

In context

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 235 are open to participants now.

Of its 158 completed or terminated interventional studies of FDA-regulated products, 109 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women attending interventional antenatal clinics during the 6-month study

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,210 participants (actual)

Study arms

  • Experimental
    Multiple Micronutrient Supplement (MMS) supplied to clinic

    Dietary Supplement: Multiple Micronutrient Supplement

Interventions

  • Dietary supplementMultiple Micronutrient Supplement

    Multiple micronutrient supplementation (MMS) which includes iron, folic acid, and additional micronutrients,

06

What researchers measure

Primary outcomes

  1. Proportion with first supplement filled by MMS

    Among pregnant women presenting for their first antenatal visit during the 6-month intervention period at one of the intervention clinics who then deliver at one of the Tsepamo sites, the proportion for whom the first supplement filled during pregnancy is MMS. As comparators, we will use the 6-month pre-intervention period at the intervention clinics and the 6-month intervention period at non-intervention clinics (all non-intervention clinics as well as specific preselected control clinics).

    Time frame: 6-month intervention period

Secondary outcomes

  1. Implementation: Proportion for which MMS is filled

    This outcome will be evaluated using data from clinic logbooks and by subtracting the number of supplements remaining in the clinic at the end of the study from the number of supplements provided to the clinic

    Time frame: 6-month intervention period

  2. Implementation: Proportion for which first and second supplement filled by MMS

    Among pregnant women presenting for their first antenatal visit during the 6-month intervention period at one of the intervention clinics who then deliver at one of the Tsepamo sites, the proportion for whom MMS is filled at the first and second antenatal visit. This outcome will be evaluated through linkage with the Tsepamo Study. As comparators, we will use the 6-month pre-intervention period at the intervention clinics and the 6-month intervention period at non-intervention clinics (all non-intervention clinics as well as specific preselected control clinics).

    Time frame: 6-month intervention period

  3. Implementation: Feasibility

    Feasibility of the intervention will be measured via qualitative pre- and post- intervention surveys among staff at the intervention clinics. Questions will be asked using a Likert scale ranging from completely disagree to completely agree. We will report the mean/median response for each question as well as the mean/median change in score between the pre and post surveys. As this is a qualitative measure there is no predefined minimum or maximum value.

    Time frame: 8 months

  4. Clinical: Number of Pregnant Women with an Adverse Birth Outcome

    1\) Any adverse birth outcome, consisting of stillbirth, preterm birth, SGA, neonatal death (as well as individual birth outcomes) among those who deliver at one of the Tsepamo sites. . As comparators, we will use the 6-month pre-intervention period at the intervention clinics and the 6-month intervention period at non-intervention clinics (all non-intervention clinics as well as specific preselected control clinics).

    Time frame: 6-months

  5. Clinical: Weight Gain in Pregnancy

    Weight gain in pregnancy among those who deliver at one of the Tsepamo sites. As comparators, we will use the 6-month pre-intervention period at the intervention clinics and the 6-month intervention period at non-intervention clinics (all non-intervention clinics as well as specific preselected control clinics).

    Time frame: 6-months

  6. Clinical: Number of mothers diagnosed with Maternal Anemia

    Number of mothers diagnosed with Anemia during the six month intervention or percentage of mothers diagnosed with anemia during 6 months of intervention compared to the percentage of mothers diagnosed with anemia in the 6 months prior to the intervention or 6 months after the interventions was completed.

    Time frame: 6-months

07

Study locations

13 sites
  • Kgatelopele (Block 8)
    Block 8, Gaborone, Botswana
  • Gabarone West Clinic
    Gaborone, Gaborone, Botswana
  • Lesirane Clinic
    Gaborone, Gaborone, Botswana
  • Mahlaku Lekganyane (Mmopane Block 1)
    Gaborone, Gaborone, Botswana
  • Nkoyaphiri Clinic
    Gaborone, Gaborone, Botswana
  • Tlokweng Main Clinic
    Gaborone, Gaborone, Botswana
  • Kopong Clinic
    Kopong, Molepolole, Botswana
  • Borakalalo
    Molepolole, Molepolole, Botswana
  • Boribamo Clinic
    Molepolole, Molepolole, Botswana
  • Boswelakoko-Borakalalo New Clinic
    Molepolole, Molepolole, Botswana
  • Phuthadikobo Clinic
    Molepolole, Molepolole, Botswana
  • Kediretswe Clinic
    Palapye, Palapye, Botswana
  • Palapye Primary Hospital
    Palapye, Botswana
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Jan 2026, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2022
First posted
Jan 30, 2023
StartActual
Jul 9, 2024
Primary completionActual
Jan 13, 2026
CompletionActual
Jan 13, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05703373
Responsible party
Ellen Caniglia (Assistant Professor of Epidemiology in Biostatistics and Epidemiology, University of Pennsylvania) — Principal investigator
First posted
Jan 30, 2023
Start date
Jul 9, 2024
Primary completion
Jan 13, 2026
Completion
Jan 13, 2026
Last update
Aug 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion